DARATUMUMAB-LENALİDOMİD-DEKSAMETAZON(DRD) PROTOKOLÜ

Kaynaklar:

1- Meletios A. Dimopoulos, M.D., Albert Oriol, M.D., Hareth Nahi, M.D., Jesus San-Miguel, M.D., Nizar J. Bahlis, M.D., Saad Z. Usmani, M.D., Neil Rabin, M.B., B.S., Ph.D., Robert Z. Orlowski, M.D., Mieczyslaw Komarnicki, M.D., Kenshi Suzuki, M.D., Torben Plesner, M.D., Sung-Soo Yoon, M.D., Dina Ben Yehuda, M.D., Paul G. Richardson, M.D., Hartmut Goldschmidt, M.D., Donna Reece, M.D., Steen Lisby, M.D., Nushmia Z. Khokhar, M.D., Lisa O’Rourke, M.S.N., Christopher Chiu, Ph.D., Xiang Qin, M.S., Mary Guckert, M.S.N., Tahamtan Ahmadi, M.D., and Philippe Moreau, M.D. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. The New England Journal of Medicine. 2016. October 375 (14): 1319-1331

2- Dimopoulos, M. A., A. Oriol, H. Nahi, et al. 2016. "Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma." N Engl J Med 375(14):1319-1331.

3- Quach, H., S. Benson, H. Haysom, et al. 2018. "Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma." Intern Med J 48(2):210-220.

4-Morgan, G. J., J. A. Child, W. M. Gregory, et al. 2011. "Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial." Lancet Oncol 12(8):743-752.

5-Bahlis, N., M. Dimopoulos, D. White, et al. 2018. “Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)”. Blood 132: 1996.

6- Plesner T, Arkenau HT, Lokhorst HM, et al. Daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: updated results of a phase 1/2 study (GEN503). Presented at the American Society of Hematology 57th Annual Meeting and Exposition, Orlando, FL, December 5–8, 2015.